Oncobiologics reported quarterly EPS of -$0.16, missing the Zacks Consensus Estimate of -$0.12 by $0.04 per share. The loss was narrower than the -$0.40 per share reported a year ago, but the miss versus expectations is a modest negative for the stock.
Oncobiologics reported quarterly EPS of -$0.16, missing the Zacks Consensus Estimate of -$0.12 by $0.04 per share. The loss was narrower than the -$0.40 per share reported a year ago, but the miss versus expectations is a modest negative for the stock.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly negative
Sentiment Score
-0.25
Ticker Sentiment
